ClinicalTrials.gg
TerminatedNCT01562041Updated Jun 18, 2021Results posted

Evaluation of Exercise Treadmill Test (ETT) Indices in Participants With Cardiovascular Disease

A Phase 2 interventional study of Ranolazine 500 mg in Atherosclerotic Coronary Vascular Disease, sponsored by Novartis Pharmaceuticals. Terminated at 2 sites in United States. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-06-18.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
40 Years to 75 Years
Sex
All
01

Study summary

The study was designed to evaluate the use of ETT electrocardiogram (ECG) indices as biomarkers in the assessment of atherosclerotic coronary vascular disease (ASCVD).

02

Conditions studied

  • Atherosclerotic Coronary Vascular Disease

Keywords

  • Cardiovascular disease
  • Exercise Treadmill Test
  • Ranolazine
  • Angina
  • Myocardial ischemia
03

In context

Cardiovascular Diseases

5,370 studies on the registry are indexed under Cardiovascular Diseases; 938 are open to participants now.

This study's enrollment of 14 is below the median of 100 across 3,084 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • History of stable coronary artery disease

Exclusion criteria

Exclusion Criteria:

  • Inability or unwillingness to participate in multiple exercise treadmill tests and/or any other requirements of this study as assessed by the Investigator.

    • History of chronic atrial fibrillation.

Other protocol-defined inclusion/exclusion criteria may apply.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Ranolazine 500 mg

    Participants received ranolazine 500 milligrams (mg), orally, twice daily (b.i.d.) up to 14 days.

    Drug: Ranolazine 500 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Maximum ST Segment Change Adjusted for Heart Rate (ST-HR) Index

    ST/HR index was measured as the average change in ST segment depression relative to heart rate change over the entire duration of exercise, monitored by ECG during the exercise treadmill tests. Change in maximum ST/HR index between the average of tests 1-3 (pre Ranexa® treatment) performed during baseline period and test 4 (post Ranexa® treatment) during treatment period was reported.

    Time frame: Baseline up to Day 15

  2. Change From Baseline in Maximum ST Segment Change Adjusted for Heart Rate (ST-HR) Slope

    ST-HR slope is an index of exercise induced ischemia. Linear regression was used to determine the slope of the ST/HR relationship in a participant's ECG response monitored during the exercise treadmill test. The highest ST segment/heart rate slope from among all the ECG leads and the X-axis intercept of the associated line were used to generate the maximum slope. Change in maximum ST-HR slope between the average of tests 1-3 (pre Ranexa® treatment) performed during baseline period and test 4 (post Ranexa® treatment) during treatment period was reported.

    Time frame: Baseline up to Day 15

  3. Change From Baseline in X-Axis Intercept of ST-HR Slope

    Linear regression was used to determine the slope of the ST/HR relationship in a participant's ECG response monitored during the exercise treadmill test. Change in X- axis intercept of ST-HR slope between the average of tests 1-3 (pre Ranexa® treatment) performed during baseline period and test 4 (post Ranexa® treatment) during treatment period was reported.

    Time frame: Baseline up to Day 15

Secondary outcomes

  1. Change From Baseline in Total Exercise Duration

    Total exercise duration was defined as the elapsed time between the start of exercise and termination of exercise for severe angina, dyspnea or extreme fatigue assessed during the exercise treadmill test. Change in the duration of exercise between the average of tests 1-3 (pre Ranexa® treatment) performed during baseline period and test 4 (post Ranexa® treatment) during treatment period was reported.

    Time frame: Baseline up to Day 15

  2. Change From Baseline in Time to Onset of 1 mm ST Segment Depression (Time to Ischemia)

    Exercise-induced ischemia was defined as the new development of horizontal or down sloping ST-segment depression (≥ 1 mm at 60 milliseconds after the J point) vs. baseline tracings. Change in time to onset of 1 mm ST depression between the average of tests 1-3 (pre Ranexa® treatment) performed during baseline period and test 4 (post Ranexa® treatment) during treatment period was reported.

    Time frame: Baseline up to Day 15

  3. Change From Baseline in Time to Onset of Angina

    Time to onset of angina was defined as the elapsed time between the start of exercise and the onset of anginal chest pain as reported by the participant. Change in time to angina between the average of tests 1-3 (pre Ranexa® treatment) performed during baseline period and test 4 (post Ranexa® treatment) during treatment period was reported.

    Time frame: Baseline up to Day 15

07

Results

Posted Jun 18, 2021

Participant flow

A total of 14 participants took part in the study from 9 March 2012 to 2 January 2014.

Participant flow — Overall Study
MilestoneRanolazine 500 mg
Started14
Completed14
Not completed0

Outcome measures

PrimaryChange From Baseline in Maximum ST Segment Change Adjusted for Heart Rate (ST-HR) Index

ST/HR index was measured as the average change in ST segment depression relative to heart rate change over the entire duration of exercise, monitored by ECG during the exercise treadmill tests. Change in maximum ST/HR index between the average of tests 1-3 (pre Ranexa® treatment) performed during baseline period and test 4 (post Ranexa® treatment) during treatment period was reported.

Time frame:
Baseline up to Day 15
Reported as:
Mean · microvolts/beats per minute (microV/bpm)
Change From Baseline in Maximum ST Segment Change Adjusted for Heart Rate (ST-HR) Index
microvolts/beats per minute (microV/bpm)Ranolazine 500 mg
Test 13.211 ± 1.6553
Test 22.822 ± 1.0289
Test 33.228 ± 1.8910
Test 42.502 ± 1.8884
Change From Baseline in Maximum ST/Heart Rate Index-0.605 ± 1.0482
PrimaryChange From Baseline in Maximum ST Segment Change Adjusted for Heart Rate (ST-HR) Slope

ST-HR slope is an index of exercise induced ischemia. Linear regression was used to determine the slope of the ST/HR relationship in a participant's ECG response monitored during the exercise treadmill test. The highest ST segment/heart rate slope from among all the ECG leads and the X-axis intercept of the associated line were used to generate the maximum slope. Change in maximum ST-HR slope between the average of tests 1-3 (pre Ranexa® treatment) performed during baseline period and test 4 (post Ranexa® treatment) during treatment period was reported.

Time frame:
Baseline up to Day 15
Reported as:
Mean · microvolts/beat/minute (microV/beat/min)
Change From Baseline in Maximum ST Segment Change Adjusted for Heart Rate (ST-HR) Slope
microvolts/beat/minute (microV/beat/min)Ranolazine 500 mg
Test 14.857 ± 2.3042
Test 25.318 ± 3.0996
Test 34.645 ± 2.2869
Test 43.430 ± 2.7374
Change From Baseline in Maximum ST/Heart Rate Slope-1.553 ± 3.1200
PrimaryChange From Baseline in X-Axis Intercept of ST-HR Slope

Linear regression was used to determine the slope of the ST/HR relationship in a participant's ECG response monitored during the exercise treadmill test. Change in X- axis intercept of ST-HR slope between the average of tests 1-3 (pre Ranexa® treatment) performed during baseline period and test 4 (post Ranexa® treatment) during treatment period was reported.

Time frame:
Baseline up to Day 15
Reported as:
Mean · beats per minute (bpm)
Change From Baseline in X-Axis Intercept of ST-HR Slope
beats per minute (bpm)Ranolazine 500 mg
Test 193.4 ± 21.33
Test 288.1 ± 27.30
Test 389.8 ± 19.39
Test 489.2 ± 24.34
Change From Baseline in X-axis Intercept of ST/Heart Rate Slope2.173 ± 8.7326
SecondaryChange From Baseline in Total Exercise Duration

Total exercise duration was defined as the elapsed time between the start of exercise and termination of exercise for severe angina, dyspnea or extreme fatigue assessed during the exercise treadmill test. Change in the duration of exercise between the average of tests 1-3 (pre Ranexa® treatment) performed during baseline period and test 4 (post Ranexa® treatment) during treatment period was reported.

Time frame:
Baseline up to Day 15
Reported as:
Mean · minutes
Change From Baseline in Total Exercise Duration
minutesRanolazine 500 mg
Test 111.118 ± 3.3519
Test 211.008 ± 3.3765
Test 311.150 ± 3.4652
Test 411.892 ± 3.7094
Change From Baseline in Total Exercise Duration0.755 ± 0.9834
SecondaryChange From Baseline in Time to Onset of 1 mm ST Segment Depression (Time to Ischemia)

Exercise-induced ischemia was defined as the new development of horizontal or down sloping ST-segment depression (≥ 1 mm at 60 milliseconds after the J point) vs. baseline tracings. Change in time to onset of 1 mm ST depression between the average of tests 1-3 (pre Ranexa® treatment) performed during baseline period and test 4 (post Ranexa® treatment) during treatment period was reported.

Time frame:
Baseline up to Day 15
Reported as:
Mean · minutes
Change From Baseline in Time to Onset of 1 mm ST Segment Depression (Time to Ischemia)
minutesRanolazine 500 mg
Test 18.611 ± 3.8054
Test 28.833 ± 3.2241
Test 39.196 ± 3.6141
Test 49.343 ± 4.1114
Change From Baseline in Time to Onset of 1 mm ST Depression0.876 ± 1.0227
SecondaryChange From Baseline in Time to Onset of Angina

Time to onset of angina was defined as the elapsed time between the start of exercise and the onset of anginal chest pain as reported by the participant. Change in time to angina between the average of tests 1-3 (pre Ranexa® treatment) performed during baseline period and test 4 (post Ranexa® treatment) during treatment period was reported.

Time frame:
Baseline up to Day 15
Reported as:
Mean · minutes
Change From Baseline in Time to Onset of Angina
minutesRanolazine 500 mg
Test 18.693 ± 2.4635
Test 27.575 ± 1.9806
Test 38.189 ± 1.5457
Test 48.037 ± 3.6395
Change From Baseline in Time to Onset of Angina0.473 ± 3.3342

Adverse events

Collected over From Baseline up to end of study, approximately 21 days.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ranolazine 500 mg0/14 (0%)0/14 (0%)3/14 (21.4%)
Most frequent other events
Most frequent other events
EventRanolazine 500 mg
NAUSEAGastrointestinal disorders1/14
DIZZINESSNervous system disorders1/14
HaematuriaRenal and urinary disorders1/14
NIGHT SWEATSSkin and subcutaneous tissue disorders1/14

Baseline characteristics

Safety Analysis Set included all enrolled participants who met the inclusion/exclusion criteria and had at least one post-baseline assessment.

Age, Continuous
Age, Continuous(years)Ranolazine 500 mg
Mean64.0 ± 7.75
Sex: Female, Male
Sex: Female, Male(Participants)Ranolazine 500 mg
Female4
Male10
08

Study locations

2 sites
  • Novartis Investigative Site
    Jacksonville, Florida 32216, United States
  • Novartis Investigative Site
    New York, New York 10021, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2012 to primary completion in Jan 2014, 21 months.

Results were first posted in Jun 2021, 7 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2012
First posted
Mar 23, 2012
StartActual
Mar 9, 2012
Primary completionActual
Jan 2, 2014
CompletionActual
Jan 2, 2014
Results first posted
Jun 18, 2021
Last update
Jun 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01562041
Responsible party
Sponsor
First posted
Mar 23, 2012
Start date
Mar 9, 2012
Primary completion
Jan 2, 2014
Completion
Jan 2, 2014
Results posted
Jun 18, 2021
Last update
Jun 18, 2021

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranolazine

Start the discussion